Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?

Abstract

Innate immune checkpoint CD47 has emerged as a prominent target for cancer immunotherapy and defining biomarkers predictive of response will be a crucial step towards clinical implementation. Hereto, we investigated the importance of a previously reported requisite for SLAM family member 7(SLAMF7) expression on cancer cell phagocytosis for effective CD47 antibody therapy.

Keywords

• slamf7
• cd47
• phagocytosis
• dlbcl